"versionIdentifier","rationale","instanceType","id","uuid:ID"
"2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion","StudyVersion_1","f0021544-1c62-4797-bf37-a2d2fe08056e"
